HDAC8: a multifaceted target for therapeutic interventions.

dc.creatorChakrabarti, Alokta
dc.creatorOehme, Ina
dc.creatorWitt, Olaf
dc.creatorOliveira, Guilherme Correa de
dc.creatorSippl, Wolfgang
dc.creatorRomier, Christophe
dc.creatorPierce, Raymond John
dc.creatorJung, Manfred
dc.date2016-02-11T12:39:04Z
dc.date2016-02-11T12:39:04Z
dc.date2015
dc.date.accessioned2023-09-27T00:16:15Z
dc.date.available2023-09-27T00:16:15Z
dc.identifierCHAKRABARTI, Alokta et al. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci., vol. 36, n. 7, p. 481-492, 2015.
dc.identifier0165-6147
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/12712
dc.identifier10.1016/j.tips.2015.04.013
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8899159
dc.descriptionHistone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major ‘epigenetic player’ that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier Inc
dc.rightsopen access
dc.subjecthistone deacetylases
dc.subjectHDAC8
dc.subjectCornelia de Lange syndrome
dc.subjectcancer
dc.subjectschistosoma
dc.subjectX-ray crystallography
dc.titleHDAC8: a multifaceted target for therapeutic interventions.
dc.typeArticle


Este ítem pertenece a la siguiente institución